Abstract
The ex vivo priming and expansion of human cytotoxic T lymphocytes (CTLs) has potential for use in immunotherapy applications for cancer and infectious diseases. To overcome the difficulty in obtaining sufficient numbers of CTLs, we have developed artificial antigen-presenting cells (aAPCs) expressing ligands for the T-cell receptor (TCR) and the CD28 and 4-1BB co-stimulatory surface molecules. These aAPCs reproducibly activate and rapidly expand polyclonal or antigen-specific CD8(+) T cells. The starting repertoire of CD8+ T cells was preserved during culture. Furthermore, apoptosis of cultured CD8(+) T cells was diminished by this approach. This approach may have important therapeutic implications for adoptive immunotherapy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antigen-Presenting Cells / immunology*
-
Antigens, CD
-
Apoptosis
-
CD28 Antigens / metabolism*
-
CD8-Positive T-Lymphocytes / metabolism
-
Cell Line
-
Cell Separation
-
Cells, Cultured
-
Coculture Techniques
-
Flow Cytometry
-
Humans
-
Immunotherapy, Adoptive / methods
-
K562 Cells
-
Ligands
-
Protein Binding
-
Receptors, Antigen, T-Cell / metabolism*
-
Receptors, Nerve Growth Factor / metabolism*
-
Receptors, Tumor Necrosis Factor / metabolism*
-
Reverse Transcriptase Polymerase Chain Reaction
-
T-Lymphocytes, Cytotoxic / cytology*
-
T-Lymphocytes, Cytotoxic / immunology*
-
Time Factors
-
Tumor Necrosis Factor Receptor Superfamily, Member 9
Substances
-
Antigens, CD
-
CD28 Antigens
-
Ligands
-
Receptors, Antigen, T-Cell
-
Receptors, Nerve Growth Factor
-
Receptors, Tumor Necrosis Factor
-
TNFRSF9 protein, human
-
Tumor Necrosis Factor Receptor Superfamily, Member 9